Degarelix (INN) or degarelix acetate (USAN) (trade name Firmagon) has an immediate onset of action, binding to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocking their interaction with GnRH. This induces a fast and profound reduction in luteinising hormone (LH), follicle-stimulating hormone (FSH) and in turn, testosterone suppression. Testosterone is a male hormone that promotes growth of many prostate tumours..
CAT No: 10-101-132
CAS No:214766-78-6
Synonyms/Alias:Degarelix;214766-78-6;Firmagon;Uglypeptide1;SX0XJI3A11;FE200486;UNII-SX0XJI3A11;CHEMBL415606;FE-200486 (free base);HSDB 7817;FE200486 ANHYDROUS FREE BASE;FE200486 (AS ACETATE SALT);FE-200486 ANHYDROUS FREE BASE;DEGARELIX (MART.);DEGARELIX [MART.];D-Alaninamide, N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-;degarelixum;Degarelix [INN];Degarelix (Standard);Degarelix (acetate)?;DEGARELIX [MI];Degarelix (INN/USAN);DEGARELIX [HSDB];DEGARELIX [USAN];DEGARELIX [VANDF];DEGARELIX [WHO-DD];DEGARELIX [EMA EPAR];Degarelix [USAN:INN:BAN];GTPL5585;SCHEMBL1397034;DEGARELIX ACETATE [JAN];SCHEMBL21050504;L02BX02;CHEBI:135961;DTXSID801026401;GLXC-26186;HY-16168AR;BDBM50102450;HY-16168A;NSC771648;AKOS030526717;CS-5350;DB06699;NSC-771648;AS-82636;D08901;F85338;EN300-20626108;Q1182795;Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2;Ac-D-2Nal-D-Phe(4-Cl)-D-3Pal-Ser-Phe(4-S-dihydroorotamido)-D-Phe(4-ureido)-Leu-Lys(iPr)-Pro-D-Ala-NH2;Acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide;N-Acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N(sup 6)-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide;N-acetyl-3-(naphtalen-2-yl)-D-alanyl-4-chloro-D-phenylalanyl-3-(pyridin-3-yl)-D-alanyl-L-seryl-4-((((4S)-2,6-dioxohexahydropyrimidin-4-yl)carbonyl)amino)-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide;
1. Implications of ligand-receptor binding kinetics on GLP-1R signalling
2. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
3. SERS spectrum of the peptide thymosin‐β4 obtained with Ag nanorod substrate
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More